Non-Cystic Fibrosis Bronchiectasis Therapeutics Market Size in the 7MM was ~USD 1,455.1 million in 2023, is projected to increase by 2034 with a CAGR of ~14.5% | DelveInsight

DelveInsight's "Non-Cystic Fibrosis Bronchiectasis Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of NCFB, historical and forecasted epidemiology, as well as the NCFB market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Explore the intricate details of the Non-Cystic Fibrosis Bronchiectasis Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive Non-Cystic Fibrosis Bronchiectasis Market Forecast. Click here to stay ahead in healthcare innovation @ Non-Cystic Fibrosis Bronchiectasis Market Size [https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Non-Cystic Fibrosis Bronchiectasis Market Report

* The total diagnosed prevalent cases of NCFB were approximately 1,028,651 in 2023. This number is anticipated to rise during the forecast period (2024-2034), driven by increased awareness and screening, along with advancements in diagnostic techniques.
* In 2023, the US accounted for the highest number of diagnosed prevalent cases of NCFB, with approximately 380,711 cases, while France accounted for the least, with only 37,576 cases.
* Among EU4 and the UK, the UK accounted for the highest number of diagnosed prevalent cases of NCFB, with approximately 224,976 cases in 2023, followed by Spain with approximately 149,236 cases, and Italy with nearly 89,584 cases.
* Among the severity-specific diagnosed prevalent cases of NCFB in EU4 and the UK in 2023, there were approximately 235,481 moderate cases, around 163,649 severe cases, and 152,230 mild cases.
* Among the gender-specific cases of NCFB in the UK in 2023, there were approximately 130,486 cases for females and around 94,490 cases for males.
* The leading Non-Cystic Fibrosis Bronchiectasis Companies such as AstraZeneca, GlaxoSmithKline (GSK), Novartis, Boehringer Ingelheim, Roche, Pfizer, Vertex Pharmaceuticals, Genentech, Chiesi Pharmaceuticals, Teva Pharmaceutical Industries , and others
* Promising Non-Cystic Fibrosis Bronchiectasis Therapies such as Brensocatib, Colistimethatesodium, Trikafta, CHF 6333, S-1226, CMS, BI 1323495, ARINA-1, TIP, ALX-009 , and others

Navigate the complexities of the Non-Cystic Fibrosis Bronchiectasis Market: gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Non-Cystic Fibrosis Bronchiectasis Market Forecast. Click here to get more insights @ Non-Cystic Fibrosis Bronchiectasis Treatment Market Size [https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Non-Cystic Fibrosis Bronchiectasis Epidemiology Segmentation in the 7MM

* Total Non-Cystic Fibrosis Bronchiectasis diagnosed prevalent cases
* Non-Cystic Fibrosis Bronchiectasis severity-specific diagnosed prevalent cases
* Non-Cystic Fibrosis Bronchiectasis gender-specific diagnosed prevalent cases
* Non-Cystic Fibrosis Bronchiectasis etiology-specific diagnosed prevalent cases
* Non-Cystic Fibrosis Bronchiectasis microbiology patients

Download the report to understand which factors are driving Non-Cystic Fibrosis Bronchiectasis epidemiology trends @ Non-Cystic Fibrosis Bronchiectasis Prevalence [https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Non-Cystic Fibrosis Bronchiectasis Emerging Drugs

* Brensocatib: Insmed/AstraZeneca

Brensocatib, an oral small-molecule inhibitor targeting dipeptidyl peptidase 1 (DPP1), is being developed by Insmed for the treatment of bronchiectasis, CRSsNP, and other neutrophil-driven conditions. By inhibiting DPP1, brensocatib aims to reduce inflammation by blocking the activation of neutrophil serine proteases (NSPs), such as neutrophil elastase, during neutrophil formation in the bone marrow. Insmed reported positive topline results from the Phase III ASPEN study of brensocatib in patients with NCFB, leading to plans for a New Drug Application (NDA) submission to the US FDA in late 2024. If approved, brensocatib is expected to launch in the US by mid-2025, followed by launches in Europe and Japan in the first half of 2026. In October 2024, Insmed shared positive late-breaking subgroup data from the Phase III ASPEN study of brensocatib for patients with NCFB at the CHEST 2024 Annual Meeting. Furthermore, the EMA approved a Pediatric Investigational Plan for brensocatib in NCFB patients, and brensocatib has gained access to the PRIME scheme and Breakthrough Therapy Designation for adult NCFB patients.

* Inhaled Colistimethate Sodium (CMS I-neb): Zambon

CMS I-neb is an investigational inhaled therapy for adults with NCFB colonized by P. aeruginosa, potentially offering a first-in-class treatment option. It uses colistimethate sodium, a prodrug of colistin, a polymyxin antibiotic targeting aerobic Gram-negative pathogens, including drug-resistant P. aeruginosa. By disrupting the bacterial cell membrane, colistin causes cell death and serves as a last-resort treatment for infections like carbapenem-resistant P. aeruginosa. In September 2024, Zambon released the results of the Phase III PROMIS-I and PROMIS-II studies in The Lancet Respiratory Medicine journal. The Phase III PROMIS-I trial demonstrated a significant reduction in pulmonary exacerbation rates. Although the PROMIS-II trial was terminated early due to the pandemic, pre-pandemic data showed consistency with PROMIS-I outcomes. Zambon is working with regulatory authorities to expedite patient access. The US FDA has granted CMS I-neb Breakthrough Therapy Designation (BTD), as well as QIDP and Fast Track Designation (FTD).

* FASENRA (benralizumab): AstraZeneca

FASENRA (benralizumab) is a monoclonal antibody that targets the IL-5 receptor alpha on eosinophils, facilitating the recruitment of natural killer cells to induce apoptosis, resulting in rapid and near-complete depletion of blood and tissue eosinophils in most patients. FASENRA is currently under investigation for treating adult patients with Non-Cystic Fibrosis Bronchiectasis associated with eosinophilic inflammation (NCFB + EI). According to clinicaltrials.gov, FASENRA completed Phase III clinical trials for this indication in April 2024.

Non-Cystic Fibrosis Bronchiectasis Treatment Market

The Non-Cystic Fibrosis Bronchiectasis treatment involves several drug classes tailored to manage symptoms, reduce exacerbations, and control underlying inflammation. Antibiotics, both oral and inhaled, are essential for managing chronic bacterial colonization, particularly against pathogens like P. aeruginosa. Macrolides, often used for their anti-inflammatory properties, are beneficial in reducing exacerbation frequency. Bronchodilators, including beta-agonists and anticholinergics, help alleviate airway obstruction, while corticosteroids are used to address inflammation, although their role remains limited due to potential side effects. Mucolytic agents improve mucus clearance, and emerging anti-inflammatory agents targeting neutrophilic inflammation, such as DPP1 inhibitors, represent innovative approaches. Together, these drug classes form a comprehensive yet evolving treatment landscape for NCFB, addressing its multifaceted pathophysiology.

Unlock insights into the Non-Cystic Fibrosis Bronchiectasis Market: discover drug uptake patterns, treatment landscapes, and epidemiological insights with our exclusive Non-Cystic Fibrosis Bronchiectasis Market Forecast. Click here @ Non-Cystic Fibrosis Bronchiectasis Market Drivers and Barriers [https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Non-Cystic Fibrosis Bronchiectasis Market Outlook

The Non-Cystic Fibrosis Bronchiectasis market is poised for significant growth due to the evolving landscape of pharmacological and non-pharmacological interventions addressing the complex pathophysiology of the disease. Current therapeutic strategies encompass a range of drug classes, including antibiotics, corticosteroids, bronchodilators, and mucolytics, with inhaled antibiotics demonstrating efficacy in managing chronic bacterial infections and reducing exacerbation rates. Emerging therapies, such as Brensocatib, a Dipeptidyl Peptidase 1 (DPP1) inhibitor, and BI 1291583, a cathepsin C inhibitor, target neutrophilic inflammation through distinct mechanisms, thereby offering novel approaches to improve patient outcomes. Additionally, investigational therapies like CMS I-neb and monoclonal antibodies such as FASENRA and Itepekimab present further options by directly targeting specific inflammatory pathways associated with eosinophilic inflammation. The incorporation of non-pharmacological approaches, particularly Airway Clearance Techniques (ACTs), complements pharmacological regimens, enhancing mucus clearance and preventing infection. However, the market faces challenges, including a lack of consensus guidelines and under-researched therapies like mucolytics and hyperosmolar agents, which may hinder optimal patient management.

Scope of the Non-Cystic Fibrosis Bronchiectasis Market Report

* Coverage- 7MM
* Study Period- 2020-2034
* Non-Cystic Fibrosis Bronchiectasis Companies- AstraZeneca, GlaxoSmithKline (GSK), Novartis, Boehringer Ingelheim, Roche, Pfizer, Vertex Pharmaceuticals, Genentech, Chiesi Pharmaceuticals, Teva Pharmaceutical Industries, and others
* Non-Cystic Fibrosis Bronchiectasis Therapies- Brensocatib, Colistimethatesodium, Trikafta, CHF 6333, S-1226, CMS, BI 1323495, ARINA-1, TIP, ALX-009, and others
* Non-Cystic Fibrosis Bronchiectasis Therapeutic Assessment: Non-Cystic Fibrosis Bronchiectasis Current marketed and Non-Cystic Fibrosis Bronchiectasis Emerging Therapies
* Non-Cystic Fibrosis Bronchiectasis Market Dynamics: Non-Cystic Fibrosis Bronchiectasis Market drivers and Non-Cystic Fibrosis Bronchiectasis Market Barriers

Gain a strategic edge in the Non-Cystic Fibrosis Bronchiectasis Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Non-Cystic Fibrosis Bronchiectasis Market Forecast. Click here to lead in advancements @ Non-Cystic Fibrosis Bronchiectasis Clinical Trials Assessment [https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

1. Key Insights

2. Report Introduction

3. Market Overview at a Glance

4. Epidemiology and Market Forecast Methodology

5. Executive Summary

6. Key Events

7. Disease Background and Overview

8. Patient Journey

9. Epidemiology and Patient Population

10. Emerging Drugs

11. Non-Cystic Fibrosis Bronchiectasis (NCFB): Market Analysis

12. Key Opinion Leaders' Views

13. SWOT Analysis

14. Unmet Needs

15. Market Access and Reimbursement

16. Appendix

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=noncystic-fibrosis-bronchiectasis-therapeutics-market-size-in-the-7mm-was-usd-14551-million-in-2023-is-projected-to-increase-by-2034-with-a-cagr-of-145-delveinsight]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/respiratory-domain-conference-coverage



This release was published on openPR.